GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » EBITDA Margin %

Cyclopharm (ASX:CYC) EBITDA Margin % : -50.64% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cyclopharm's EBITDA for the six months ended in Jun. 2024 was A$-6.69 Mil. Cyclopharm's Revenue for the six months ended in Jun. 2024 was A$13.21 Mil. Therefore, Cyclopharm's EBITDA margin for the quarter that ended in Jun. 2024 was -50.64%.


Cyclopharm EBITDA Margin % Historical Data

The historical data trend for Cyclopharm's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm EBITDA Margin % Chart

Cyclopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.79 -33.50 -20.18 -21.67 -12.25

Cyclopharm Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.35 -28.73 -12.79 -11.38 -50.64

Competitive Comparison of Cyclopharm's EBITDA Margin %

For the Medical Distribution subindustry, Cyclopharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm's EBITDA Margin % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cyclopharm's EBITDA Margin % falls into.



Cyclopharm EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cyclopharm's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-3.227/26.339
=-12.25 %

Cyclopharm's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-6.688/13.207
=-50.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclopharm  (ASX:CYC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cyclopharm EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cyclopharm's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclopharm Business Description

Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm Headlines

No Headlines